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Abstract  
 
Objective: Adverse effects (AEs) of antipsychotic medication have important 
implications for patients and prescribers in terms of wellbeing, treatment adherence 
and quality of life. This review summarises strategies for collecting and reporting AE 
data across a representative literature sample to ascertain their rigour and 
comprehensiveness. 
Methods: A PsycINFO search, following PRISMA Statement guidelines, was 
conducted in English-language journals (1980–July 2014) using the following search 
string: (antipsychotic* OR neuroleptic*) AND (subjective effect OR subjective 
experience OR subjective response OR subjective mental alterations OR subjective 
tolerability OR subjective wellbeing OR patient perspective OR self-rated effects OR 
adverse effects OR side-effects). Of 7,825 articles, 384 were retained that reported 
quantified results for AEs of typical or atypical antipsychotics amongst 
transdiagnostic adult, adolescent, and child populations. Information extracted 
included: types of AEs reported; how AEs were assessed; assessment duration; 
assessment of the global impact of antipsychotic consumption on wellbeing; and 
conflict of interest due to industry sponsorship. 
Results: Neurological, metabolic, and sedation-related cognitive effects were 
reported most systematically relative to affective, anticholinergic, autonomic, 
cutaneous, hormonal, miscellaneous, and non-sedative cognitive effects. The impact 
of AEs on patient wellbeing was poorly assessed. Cross-sectional and prospective 
research designs yielded more comprehensive data about AE severity and prevalence 
than clinical or observational retrospective studies. 
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Conclusions: AE detection and classification can be improved through the use of 
standardised assessment instruments and consideration of subjective patient impact. 
Observational research can supplement information from clinical trials to improve the 
ecological validity of AE data. 
 
Key words: Antipsychotic drugs; adverse effects; patient-centred research; subjective 
effects of drugs 
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Assessing and reporting the adverse effects of antipsychotic medication: A 
systematic review of clinical studies, and prospective, retrospective, and cross-
sectional research 
 
Antipsychotic medication is associated with numerous adverse effects (AEs), ranging 
from mild and intermittent (e.g., dizziness and nausea) to incapacitating (e.g., 
extrapyramidal symptoms: EPS), some of which can disrupt an array of physical and 
psychological systems.1-3 Since the institution of antipsychotics in the 1950s, it has 
been recognised that patients generate subjective interpretations of the sensations that 
attend drug consumption. However, the imperative for standardising psychiatric 
phenomena arguably led “to a gradual disregard of subjective experiences…which 
were relegated to ‘soft’ science.” 4: p.55 Correspondingly, much research has prioritized 
efficacy and safety parameters rather than the more subjective construct of 
tolerability. Interest in the latter was advanced by the work of Hogan et al.5 whose 
scale for assessing antipsychotic responses indicated that “maximum variability…is 
accounted for by items reflecting how the patient feels on medication, rather than 
what he knows or believes about medication” (p.177). In this respect patient 
testimony indicates that AEs are sometimes experienced as equally6 or more7 
distressing than the symptoms targeted by the drugs.   
The realization that AEs have implications for treatment adherence,8 quality of 
life,9 mortality,10 suicidal ideation,11  and litigation suits12 means greater attention is 
being paid to phenomenological aspects of AP use. The development of 
psychometrically robust scales that patients can reliably complete has also advanced 
the research agenda.13-15 This is important progress, given the necessity of auditing 
the relative prevalence and severity of AEs, and corresponding impact on patient 
wellbeing. In this respect, the substantial differences in AE profiles for different 
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antipsychotics (compared to robust, yet small, mean differences in efficacy)16 makes 
the former an important component of prescribing choices and, in accordance with 
best-practice guidelines, can empower service-users in making informed treatment 
decisions17 about the short- and long-term risk/benefit ratios.  
Despite the utility of assessing and documenting AEs, recording is frequently 
deficient.18-20 For example, an analysis of 182 randomised trials for assorted 
psychiatric interventions reported that 58.3% assigned more page space to authors’ 
names and affiliations than safety statistics.21 A review of safety and tolerability data 
from 167 antipsychotic trials likewise indicated numerous failings, primarily 
inconsistent measurement and inadequate or confusing reporting.22 Other authors 
have provided detailed information on global AE domains (e.g. EPS23), specific 
experiences (e.g. hyperprolactinaemia24), or the safety and tolerability profiles for 
particular classes (e.g. long-acting injections25) or brands26 of drug. However, there is 
currently a lack of comprehensive information about the methods employed for 
assessing adverse antipsychotic effects across the broader evidence base (including, 
but not limited to, clinical trials), the types of effects being reported, and whether 
screening procedures differ according to the effects being assessed. 
  
Aims of the Study  
The aim of the current review was twofold: (1) to summarise strategies employed 
across a representative literature sample for obtaining and reporting data on the 
adverse effects of antipsychotic medication, and (2) to ascertain the 
comprehensiveness and methodological rigour of these strategies. As our approach 
was an exploratory one, we had no pre-specified hypotheses. 
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Materials and Methods 
Search Procedure 
The search, extraction, and data synthesis process were informed by PRISMA 
Statement guidelines.27 Articles were searched for using the PsycINFO database 
(OVID interface) and employed the following search string: (antipsychotic* OR 
neuroleptic*) AND (subjective effect OR subjective experience OR subjective 
response OR subjective mental alterations OR subjective tolerability OR subjective 
wellbeing OR patient perspective OR self-rated effects OR adverse effects OR side-
effects). This strategy resulted in 7,825 titles and abstracts.  
 
Inclusion criteria 
Studies were sought that appeared in peer-reviewed English-language journals from 
1980 to July 2014 and reported quantified results for AEs of typical or atypical 
antipsychotics amongst transdiagnostic adult, adolescent, and child populations. 
 
Exclusion criteria 
Case studies/series, review articles, and conference proceedings were not retained. 
Also excluded were studies evaluating psychotropic medication without reporting 
specific findings for antipsychotics; studies only providing laboratory safety data; 
studies on healthy volunteers or non-psychiatric patient populations; studies reporting 
patient attitudes towards, beliefs about, and/or general wellbeing in relation to 
antipsychotic therapy without describing specific AE outcomes; studies reporting a 
single aspect (e.g., amenorrhea only) or domain (e.g., EPS only) of AEs; reports of 
augmenting antipsychotics with agents for controlling EPS; studies evaluating 
adjunctive therapies for antipsychotics as a primary outcome measure; studies 
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evaluating un-marketed or discontinued compounds. Studies only reporting a single 
global score from assessment instruments were also excluded, as it was not possible 
to code such studies according to separate AE domains. 
 
Data Extraction 
Information extracted from source papers included: date, research design, clinical 
population, participants’ mean age, and whether medication dosage and 
polypharmacy was reported. For clinical studies, data was extracted on whether the 
number of participants withdrawing due to AEs was reported, and if so, whether the 
type(s) of effect leading to discontinuation were identified. 
In order to derive a global score for the comprehensiveness of AE reporting in 
each study, the following information was extracted and coded as primary outcomes 
of interest: 
 
Adverse effect assessment  
For the purposes of the review, AEs were defined as secondary effects that are 
generally unwanted, are distinct from the medication’s therapeutic effect, are not 
necessary for its desired action, and can be experienced and identified by patients 
independent of laboratory or clinical testing.28-29 Because the review was concerned 
with known effects of antipsychotics at normal doses, data on adverse drug events 
were not retained (e.g. overdose, instances of prescribing/dispensing malpractice). 
Coding was organised according to the AE categories outlined in Table 1. For 
each domain, studies were coded 0 if no attempt was made to assess these effects, or 
if they were assessed but not reported. Assessment based on spontaneous self-report, 
observational monitoring, or unspecified checklists were coded as 1. Studies scored 2 
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if effects had been assessed using validated self-report inventories or structured 
clinical interviews. Metabolic effects were also coded as 2 if investigators provided 
numericised results pertaining to weight gain. Because the review was not assessing 
AE prevalence, studies still scored for a particular domain if no participants reported 
it, but the authors specified an intention to assess it (i.e., included a scale with relevant 
items) and/or commented on its absence.  
 
--Table 1 here-- 
 
Assessment of global impact 
In addition to quantifying AEs, clinical utility is enhanced if research addresses the 
broader impact of antipsychotic consumption on patient wellbeing. Studies that did 
not assess this, provided generalised anecdotal statements (e.g., “side-effects were 
mostly mild and transient”), or only addressed impact of pre-selected effects, such as 
EPS, were coded 0. Studies that quantified responses using non-standardised 
questionnaires (e.g., authors’ own checklist), or employed a known severity scale 
(e.g., mild, moderate, severe) across all domains of AEs were coded with 1. Studies 
assessing the subjective experience of antipsychotic usage using validated instruments 
(e.g. the Subjective Well-being Under Neuroleptics scale [SWN]13) or used AEs as 
predictors/covariates of validated outcomes (e.g., Quality of Life Enjoyment and 
Satisfaction Questionnaire [Q-LES-Q30]) were coded with 2.  
 
Timeframe 
Short-term assessment cannot provide comprehensive data on AEs with long 
induction periods (e.g. weight gain, sexual dysfunctions, amenorrhoea, tardive 
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dyskinesia). Assessment length was therefore coded as: 0= ≤ 12 weeks; 1= 13–24 
weeks; 2= ≥ 25 weeks. If treatment duration was not provided, then timeframe was 
coded according to the length of the study. For cross-sectional studies, coding was 
organized according to whether authors reported mean treatment duration.  
 
Sample size 
Larger samples have greater representation, as well as permitting identification of less 
common effects. Because no clear guidelines exist for determining adequate 
population size for antipsychotic AEs, studies were partitioned and coded according 
to the second, third and fourth percentile of the entire sample: 0= ≤ 76 (49.2%; 
n=189);  1= 77 (26.3%; n=101); 2= ≤ 225 (24.2%;  n=93). 
 
Conflict of interest 
Research subsidised by pharmaceutical companies has been shown to be more likely 
to support industry interests,31-32 including incomplete or inconsistent AE reporting,33 
or reporting more favourable AE results for the sponsor’s product relative to 
independent trials.34  Studies receiving industry funding, or in which authors declared 
receipt of honoraria from drug companies, were therefore coded with 0. Those with 
no reported affiliation were coded with 1. 
 
Global Comprehensiveness Score 
This was calculated by summing scores for each AE domain (0-18), global impact (0-
2), timeframe (0-2), sample size (0-2), and conflict of interest (0-1), resulting in a 
maximum possible score of 25 (see Table 2). 
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Analysis 
Variables related to study characteristics and comprehensiveness criteria were 
summarised using descriptive statistics. Non-parametric analyses (between-group 
comparisons for the assessment of AEs, global impact, and declared conflict of 
interest) were performed with the Kruskall-Wallis H test, Dunn’s multiple comparison 
post-hoc test, and Friedman’s two-way analysis of variance by ranks. Parametric 
analyses (timeframe, global comprehensiveness scores) were conducted using one-
way ANOVA procedures and the Tamhane T2 post-hoc comparison. Associations 
between variables were computed with Spearman’s rank correlation coefficient. All 
analyses used SPSS Statistics v.21.0 software.  
 
Reliability checking 
Data were extracted and coded by the first author and entered into an electronic data 
collection form, which was subsequently re-checked for missing or incorrect entries. 
Data deemed ambiguous were discussed and categorised in consultation with the 
second author, with any discrepancies resolved by consensus. Rating was not blinded 
to author or results. 
As a reliability measure, 16 articles were randomly selected and coded by an 
independent rater. Values were compared and inter-rater reliability calculated using 
Cohen’s κ. Of the 13 categories, seven showed 100% agreement, five 93.8% 
agreement (κ = .88), and one 87.5% agreement (κ = .76). Using Landis and Koch’s35 
guidelines, in which a κ value of >.70 suggests strong concordance, all variables 
indicated good reliability.  
 
Results 
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Of the recovered publications, 819 fulfilled criteria on the basis of title and abstract 
review and were retrieved to assess inclusion eligibility. Three articles could not be 
located. Of the remaining papers, 384 met criteria and were retained for review. These 
were subsequently organised according to four research designs: retrospective 
observational (n=40), prospective observational (n=50), cross-sectional (n=67), and 
clinical intervention (n=227). 
Sample characteristics are presented in Table 2. The most common population 
was psychosis patients (222; 57.8%), followed by developmental disorders (30; 7.8%) 
and bipolar disorder (25; 6.5%). The majority of studies recruited adults (259; 
67.45%), with a smaller number reporting results from child/adolescent samples (66; 
17.2%), elderly participants (32; 8.3%), or mixed age groups (27; 7.0%). Medication 
dosage was reported in 331 studies (86.2%) and polypharmacy in 323 (84.1%).  
 
--Table 2 here-- 
 
Assessment of Adverse Effects 
The review identified 37 instruments for assessing AEs. Table 3 presents the 10 most 
commonly used. Figure 1 displays the percentage of studies from each design 
reporting on different AEs and Figure 2 presents the percentage of studies across the 
whole sample using informal or standardised measures for each AE category. 
EPS were the most consistently assessed and reported in the sense they were 
most likely to be referred to, and more likely to be assessed using validated scales.  
This was closely followed by cognitive effects, although in many cases this was 
limited to only sedation/fatigue. When frequencies were re-calculated to determine 
the proportion of studies reporting at least one non-sedative cognitive effect  using 
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either standardised or informal measures there was a noticeable decrease: 10 
retrospective observational studies (25.0%), 38 prospective observational (76.0%), 50 
cross-sectional studies (74.6%), and 134 clinical studies (59.0%). As a weighted mean 
percentage across all four designs, this translated to a decrease from 90.7% to 60.4%. 
Of the remaining categories, metabolic and autonomic effects were reported in around 
two thirds of papers. Approximately half reported miscellaneous ‘other’, 
anticholinergic, and hormonal effects. Affective and cutaneous effects had the poorest 
measurement, being assessed or reported in less than a third of cases.  
The 0-2 coding frame was used to calculate a mean rank score of 
methodological rigour for each AE category.  Results were: EPS (7.15), metabolic 
(6.47), cognitive (6.14), autonomic (5.17), anticholinergic (4.57), ‘other’ (4.69), 
hormonal (4.12), affective (3.48), and cutaneous (3.20). Comparisons, using 
Friedman’s two-way analysis of variance, indicated that EPS scored significantly 
higher than all other categories (all p’s = .001). There was no significant difference 
between metabolic and cognitive effects, or affective and cutaneous effects (all p’s = 
1.00). Hormonal effects did not differ significantly from anticholinergic or ‘other’ 
effects, and anticholinergic effects did not differ significantly from ‘other’ or 
autonomic effects (all p’s  ≥ .086). Each of the remaining pairwise comparisons were 
significant (all p’s = .001).  
When examining mean ranks for AEs according to study design, the Kruskal-
Wallis H statistic was not significant for autonomic effects, or ‘other’ miscellaneous 
effects (all p’s ≥  .117). Of the remaining effects, post-hoc comparisons indicated that 
EPS were best assessed in clinical and cross-sectional designs (all p’s = .001), and 
metabolic effects were best assessed in clinical studies and observational prospective 
designs (all p’s = .001). Cutaneous (all  p’s ≤ .02) and anticholinergic effects (all p’s ≤  
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.034) were best assessed in cross-sectional studies. Cognitive, affective, and hormonal 
effects had the best assessment in both cross-sectional and observational prospective 
designs (all p’s ≤  .024).  
 
--Table 3 here-- 
--Figure 1 here-- 
--Figure 2 here-- 
 
Assessment of Global Impact  
Table 4 presents the measures identified in the review for assessing global impact of 
antipsychotic use. This was poorly addressed across the literature, with only 59 
studies (15.4%) employing a validated instrument to report patient experiences. Of 
these, seven did not employ the scales presented in Table 4 but calculated associations 
between AEs and standardised outcomes like the Q-LES-Q. A further 75 (19.5%) did 
not employ validated measures, but quantified AE impact with more informal criteria 
(e.g., mild/moderate/severe ratings).  
 The study designs significantly differed in assessment of global impact 
(χ2(3)=121.83, p= .001). Post-hoc comparisons indicated that mean rank scores for 
cross-sectional studies were significantly higher than the other three designs (all p’s = 
.001), with observational prospective studies scoring higher than observational 
retrospective and clinical studies (p= .001). There was no significant difference 
between observational retrospective and clinical studies (p= .27). 
 
Withdrawal from clinical studies 
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Data was additionally extracted for the number of clinical studies reporting how many 
participants withdrew due to AEs. Across the sample, only 20 (8.8%) did not address 
the issue of drug tolerability on discontinuation rates. Of the remaining 207, 50 
(22.02%) reported no drop-outs; 80 (38.6%) provided the number of withdrawals; and 
73 (35.3%) reported the numbers of withdrawals and additionally specified the types 
of effects leading to it. 
 
--Table 4 here-- 
 
Timeframe 
Across the entire sample, the mean (SD) timeframe for antipsychotic usage was 40.7 
weeks (90.6). Cross-sectional studies had the highest mean timeframe at 104.2 weeks 
(171.1), followed by prospective observational studies at 63.7 weeks (115.2), 
retrospective observational at 58.7 weeks (83.6), and clinical studies at 23.1 weeks 
(55.3). This distribution was significantly different across study designs (F(3)=11.10; 
p= .001). Post-hoc tests indicated that clinical studies reported significantly shorter 
durations than cross-sectional studies (p= .045). No other pairwise comparisons 
showed significant differences. It should also be noted that the cross-sectional studies 
had a large amount of missing or unusable data (46.3%; 31/67). This was due to 
authors either not specifying the duration of participants’ antipsychotic use, or 
reporting a broad range without providing a mean figure. 
 
Sample size 
Across all studies, the mean (SD) sample size was 576.2 (3336.6). Mean sample sizes 
according to study design are presented in Table 2, of which the largest was 
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prospective observational studies, followed by retrospective observational studies, 
cross-sectional studies, and clinical studies. Although there was significant variation 
across the sample (F(3)=7.4; p= .001), post-hoc tests did not reveal any differences 
between designs (all p’s ≥ .23). 
 
Conflict of Interest 
The design with the greatest frequency of drug company affiliations were clinical 
studies (70.0%; 159/227), followed by prospective observational (38.0%; 19/50), 
cross-sectional (23.9%; 16/67), and retrospective observational (17.5%; 7/40). This 
difference in distribution was significant (χ2(3)= 73.67, p= .001), with clinical studies  
reporting significantly more conflicts of interest than each of the other three designs 
(all p’s= .001). No other pairwise comparisons were significant. 
 
Global Comprehensiveness Rating  
There was a weak positive association between publication date and total 
comprehensiveness score across the entire sample, indicating that AE assessment and 
reporting has improved marginally over time (rs = .18, p= .001).  
There was a significant difference in scores across the four study designs 
(F(3)=27.39; p= .001). Post-hoc tests indicated no differences between cross-sectional 
and prospective observational studies (p= .08). However both these designs scored 
significantly higher than clinical studies and retrospective observational studies (all 
p’s ≤ .01). In turn, clinical studies scored significantly higher than retrospective 
observational research (p= .001).  
A post-hoc analysis was also performed to examine comprehensiveness score 
according to sample age group: adults aged ≥ 66 years (n=32), adults aged 18-65 
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years (n=259), and children/adolescents aged ≤ 17 years (n=66). Twenty seven studies 
were excluded from this analysis, either because mean age was not provided (n=11) 
or because the authors had recruited mixed samples of children/adolescents and adults 
(n=16). There was a significant difference across the sample (F(2)=218.70; p= .001). 
The mean (SD) score of 6.88 (3.07) for elderly adults was significantly lower than the 
mean of 10.77 (4.57) for adults aged 18-65, or the mean of 10.02 (3.67) for 
child/adolescent samples (all p’s = .001). There was no significant difference between 
adult and child/adolescent samples (p= .41). 
 
Discussion 
Accurate detection, classification and management of AEs is important from both 
clinical and research stances. This review systematically examined strategies used to 
record and report antipsychotic AEs, and assessed the clarity and comprehensiveness 
of these. Firstly, the results demonstrate that neurological, metabolic, and sedation-
related cognitive effects are most consistently assessed and reported across the 
literature. Secondly, the global impact of antipsychotics on patient wellbeing was 
poorly assessed. Finally, the cross-sectional and prospective research designs yielded 
the most comprehensive AE data.  
 
Assessment of Adverse Effects 
The current findings are similar to Pope et al.22 whose review of 167 antipsychotic 
trials likewise found that EPS were assessed more frequently and systematically than 
other AEs. Given their debilitating and potentially irreversible nature, it is 
encouraging that motor disturbances were carefully reported across different designs. 
Nevertheless, the reduced risk of EPS associated with atypical antipsychotics means 
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privileging their assessment over other effects may no longer be clinically justified. 
This inconsistent assessment of non-neurological effects replicates the conclusions of 
existing surveys, 22,50-51 despite concerns about the substantial impact of non-
neurological AEs on factors like physical attractiveness,52 feelings of reduced 
intelligence and creativity,53 and social stigma and ridicule.54 Furthermore, while 
sedation was generally well-reported, affective and non-sedative cognitive AEs were 
referred to far less frequently, despite patient testimony that subjective effects like 
dysphoria (e.g., feeling ‘robotic’, ‘emotionally empty,’ 53) are both common and 
distressing. 
 In addition to the types of AEs reported, limitations were also apparent in their 
assessment. An exception to this was EPS. For example, a review of 2000 
intervention studies between 1950 and 1998, 59% of which were for antipsychotics,55 
found only 17% employed either the SAS, AIMS or ESRS to assess neurological 
AEs. The current findings indicate a welcome reverse in this trend. However, non-
neurological AEs were much less likely to be assessed with validated measures. This 
is important because solicited, systematic inquiry using structured checklists is more 
likely to provide comprehensive data than open-ended questioning, which in turn is 
more efficient than spontaneous/voluntary reporting. Although the latter has the 
advantage of simplifying research protocols by reducing the number of formal 
measures participants need to complete, as well as identifying AEs that patients deem 
most relevant, there is a clear rationale for not relying on these methods alone. For 
example, Yusufi et al.56 found that memory and concentration problems were 
respectively reported by 0% and 0.1% of their participants under open-ended 
questioning, compared to 37% (38/103) and 38% (39/103) using a validated checklist. 
In turn, successful AE screening approximately doubles when spontaneous self-report 
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is supplemented with rating scales.57-58 Neither is this limited to severe effects, with 
the detection of mild to moderate problems necessitating a change in clinical 
management improving by approximately 40% using systematic checklists compared 
to open-ended inquiry.59   
It is important that research inconsistencies do not translate into mistaken 
assumptions about prevalence in clinical practice, and the privileging (for example) of 
enquiries about EPS, weight gain, and sedation over other domains. For example, 
although affective and cutaneous effects were infrequently assessed or reported across 
the sample these experiences have prevalence rates of between 38.4–66.0% 
(emotional) and 29.2–50.0% (cutaneous).60-63 Similarly, a probability sample of 243 
patients found higher rates of emotional (18.8%) and cutaneous (17.3%) effects than 
EPS such as body rigidity (11.4%) and tardive dyskinesia (7.6%; although not 
akathisia: 27.1%).64  
Further limitations in reporting and interpretation of AE data reflected those 
previously observed in existing reviews of antipsychotic trials22,65-67 as well as other 
medical disciplines.20-21 These included timeframes that were insufficient to detect 
AEs with long induction periods, inadequate detail about AE frequency/duration, 
reporting aggregated subscale scores from different measures rather than specifying 
individual effects, not reporting numericised results of Likert-scale severity measures 
and/or using ambiguous severity summaries (e.g., ‘the majority of patients were not 
troubled by AEs’; ‘AEs were mild and transient’) without providing operational 
definitions of what these terms imply. Inconsistent terminology and classification was 
also evident (e.g., ‘agitation’ without denoting cognitive AEs, psychiatric distress, or 
the neurological impact of akathisia; differentially classifying seizures as a form of 
EPS, an autonomic effect, or an unspecified ‘other’ effect). In this respect, The 
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Coding Symbols for Thesaurus of Adverse Reaction Terms68 was instigated to 
support standardised and consistent reporting. However of the 362 papers in the 
review published from 1991, only 19 referred to these guidelines. Only three cited the 
more recent Medical Dictionary for Regulatory Activities69 terminology.  
Specific limitations in the design of clinical studies included the use of first-
generation agents as comparators (which is likely to inflate EPS incidence data), only 
reporting AEs noted in at least 10% of patients or those that significantly differed 
between test and comparator drugs, not providing follow-up on withdrawn 
participants, and not clearly specifying whether cognitive/affective changes were the 
results of medication or underlying psychiatric states. Carry-over effects were also 
inconsistently addressed (e.g., if patients have gained weight from prior medication, 
weight gain may be underestimated as the potential for further increase is limited70). 
There was also a tendency to report AEs in ways which have negligible clinical 
meaning: for example, reporting sample-wide mean changes in weight, EPS scales, 
and plasma prolactin elevation as opposed to the absolute proportions of participants 
gaining weight, the number of patients reaching diagnostic threshold for movement 
disorders, or those exhibiting hyperprolactinaemia. 
 
Assessment of Global Impact 
Withdrawal rates due to AEs were reported consistently amongst the clinical studies, 
although there was negligible transparency about the types of effects precipitating 
drop-out. While separate reporting of tolerability and efficacy as reasons for 
premature discontinuation is encouraging, this failure to specify the AEs impairs the 
consistency and expediency of the measure, particularly if efficacy-related events 
(e.g., worsening of psychosis) are included in the AE category.67 Furthermore, most 
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studies prioritised quantifying AEs over establishing their subjective impact. Even 
with our lenient criteria (e.g. coding for Likert-style mild/moderate/severe indicators) 
only 34.9% of studies scored on this measure. Validated scales assessing subjective 
tolerability were particularly poorly utilised, being reported in only 15.6% of cases. 
This absence is of especial concern, given that subjective wellbeing on antipsychotics 
is identified as a major component by the Remission in Schizophrenia Working 
Group.71  
Distress from AEs “is a moving target, affected by social expectations, 
knowledge, and alternative choices” wherein objective measures of particular effects 
will not inevitably correlate with subjective impact.58: p.46 For example, distress may 
fluctuate according to the respite drugs provide from symptoms.72 Other variables 
influencing treatment satisfaction can include the quality of the therapeutic alliance,73 
shared decision-making in care planning,74 and frequency of hospital admissions.75 
Additional variations may be gender specific, with women more likely to be 
distressed by weight gain and men more likely to experience distress over sexual 
dysfunction.76 Taken together, the current results emphasise the importance of more 
proactive strategies for assessing the impact of antipsychotic consumption. For 
example, Naber13 conceptualises the global effects of antipsychotics within a five-
factor model of mental functioning, physical functioning, emotional regulation, self-
control, and social integration; subsequently expanded to include the influencing 
factors of psychopathology and symptomatic improvement, psychosocial factors, 
phase and severity of illness, attitudes toward pharmacological treatment and insight, 
and physical AEs and associated distress.77 Studies operationalising these constructs 
with the SWN13 scale report significant associations with drug compliance,13,78 with 
stronger correlations between SWN factors and depression and anxiety than SWN 
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factors and psychotic symptoms themselves.44 Our finding that AE assessment and 
reporting was significantly less rigorous in elderly populations additionally highlights 
the need for increased vigilance amongst patients for whom experiences like dementia 
and negative symptoms makes spontaneous reporting of distress more problematic. In 
summary, AEs should not be minimised as an inevitable penalty of successful 
treatment. Vigilant approaches to detection can facilitate prompt identification of 
difficulties, instigation of interventions to minimise patient burden, and ultimately 
reduce the likelihood that therapeutic impact becomes overridden by AEs. 
 
Research Designs 
Levine79defines three methodological considerations for improving AE data: 
assessment method, timeframe, and whether information permits judgments about 
cause and extent of clinical impact. This closely corresponds to our own aggregated 
coding for comprehensiveness, on which basis prospective observational and cross-
sectional designs emerged as the most comprehensive data sources. This was 
particularly owing to their larger sample sizes, greater use of standardised assessment, 
and consideration of both global drug impact and long-term antipsychotic use. 
Notwithstanding the considerable advantages of clinical trials for minimising bias and 
confounding, and for generating valuable data against placebo or comparator drugs, 
we found that AE reporting was often limited by small samples, short assessment 
durations with limited generalisability, an over-reliance on spontaneous self-report 
data, and the tendency to emphasise efficacy and symptom control over tolerability. 
Retrospective studies (which in the current review mostly encompassed medical note 
audits) can in turn generate insights into large samples of ‘real-world’ patients and 
practice, whilst remaining limited by unsystematic assessment and incomplete data. 
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Nevertheless, it is also important to acknowledge that all research designs carry 
relative strengths and limitations, and that the most comprehensive insights into AEs 
can probably be reached by considering heterogeneous evidence sources together.65 
For example, cross-sectional studies are less likely to define the nature of the 
intervention and have fewer contingencies to control confounding. Similarly, despite 
the limitations of spontaneous self-report, this method has a capacity to elicit rare or 
unexpected effects that is prohibited with standardised scales. Nevertheless, our 
findings suggest that the despite the primacy placed on clinical trials, observational 
studies are also a useful source of data for policy makers, clinicians and researchers 
seeking to understand AE prevalence and impact.  
 
Limitations  
The intention of this review was to characterise recurring themes and limitations in 
the antipsychotic literature. In this regard its main strength – a comparatively large, 
representative sample – was also the source of its main limitations. The inclusion of 
so many publications necessitated summarising a sizeable literature via broad 
conclusions. Some nuances of individual studies were not captured. Furthermore, our 
review was not pre-registered. 
Our AE coding may have reduced discriminative capacity by subsuming 
diverse experiences under a single domain (e.g., sexual dysfunctions, menstrual 
irregularities, and gynaecomastia were all categorised as ‘hormonal’). Similarly, 
inconsistent classification in the sampled studies meant reported results did not 
always correspond with our categories. For example, some authors used ‘other 
effects’ to refer to all non-neurological AEs. For subjective psychological effects, it 
was not always clear to what extent these were the result of psychosis/psychosocial 
23 
 
adversity rather than medication; as such the review may have over-estimated 
assessment rates of cognitive and emotional AEs. 
Search limitations may also have created bias. This includes our decision, 
because of the large size of the literature, to limit our search to a single database. 
Whilst our choice of PsycINFO increased the likelihood of detecting the type of 
observational, non-clinical studies in which we were interested, reliability would have 
been improved by including other databases. Similarly, the lack of double extraction 
procedures may have reduced the quality of our findings. The exclusion of non-
English language journals further risked language bias. The latter may be particularly 
relevant, as cross-cultural disparities are apparent in AE identification80and 
reporting.81-82 Demonstrated inadequacies in the ways AE data is indexed in 
electronic databases83 means relevant studies may have been missed. It is further 
possible that studies with low scores for AE assessment (e.g., small samples and 
reliant on spontaneous self-report) simply reflected a genuine absence of particular 
effects. In this respect the comprehensiveness scores were also subjectively 
operationalised. However the high inter-rater reliability, as well as consistency of the 
results with both existing literature, and between and within the four study designs, 
suggests the findings retain reasonably strong validity.  
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Table 1. Common adverse effects of antipsychotics categorised according to physiological systems. 
 
 
Effect domain 
 
 
Descriptor 
 
Examples 
 
Affective 
 
Emotional disturbances 
 
Depression, anhedonia, dysphoria, affective flattening, 
problems with emotional regulation 
 
 
Anticholinergic 
 
 
Neuromuscular inhibitions resulting from disturbance 
to acetylcholine receptors in the central and peripheral 
nervous system 
 
Dry mouth, constipation, difficulty urinating, increased 
need to urinate, blurred vision  
 
 
 
Autonomic 
 
Specific influences on the autonomic nervous system 
 
Dizziness, nausea, increased perspiration, diarrhoea, heart 
palpitations/tachycardia  
 
 
Cognitive 
 
 
Impairment to cognitive faculties 
 
Concentration difficulties, memory problems, anxiety and 
mental tension, sedation, insomnia, increased/decreased   
dreaming 
 
 
Cutaneous 
 
Hypersensitive dermatological response  
 
 
Skin rash or itchiness, dry skin, photosensitivity, acne, 
psoriasis, skin pigmentation/discolouration   
 
 
EPS 
 
Movement disorders resulting from blockade of 
dopamine receptor in the basal ganglia 
 
 
Acute dystonia, akathisia, akinesia, bradykinesia, 
dyskinesia, tremors, rigidity 
 
   
32 
 
Hormonal Sexual and somatic disturbances induced by elevated 
levels of the peptide hormone prolactin 
Amenorrhoea, anorgasmia, increased/diminished sex 
drive, erectile/ejaculatory dysfunction, gynaecomastia, 
galactorrhoea  
 
 
Metabolic  
 
Interference with normal metabolism through 
activation of SMAD3 protein  
 
 
Weight gain, polydipsia  
 
 
Other 
 
 
Additional non-specific side effects 
 
Headaches, paraesthesia, nose bleeds  
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Table 2.  Main characteristics of the studies included in the review. 
 
 
Design 
  
Clinical 
population 
 
Sample age 
 
Sample size 
 
 
Medication 
reporting 
 
 
Global 
comprehensiveness 
scorea 
 
   1. 11 ≤ 17 years 
2. 18-65 years  
3. ≥ 66 years 
4. Mixed/ 
unspecified 
 
M (SD) 
 
Range 
 
1.dosage 
2.polypharmacy 
 
M (SD) 
 
Range 
 
 
 
Retrospective 
observational 
(n=40) 
 
27 medical record audit 
7 post-marketing   
   surveillance/   
   pharmacovigilance     
   data  
5 retrospective   
   evaluation  
1 staff census  
 
 
18 transdiagnostic 
10 psychosis  
5 bipolar  
3 dementia  
1 PTSD  
1 psychotic  
   depression 
1 mood disorders 
1 delirium 
 
 
11 (27.50%) 
17 (42.50%) 
7 (17.50%) 
5 (12.50%) 
 
 
 
1118.85 
(3627.30) 
 
10 – 20592 
 
33 (82.50%) 
33 (82.50%) 
 
 
7.70 (2.23) 
 
4–13 
 
Prospective 
observational 
(n=50) 
 
  
36 psychosis 
9 transdiagnostic 
2 DD 
3 dementia 
 
 
5 (10.0%) 
39 (78.0%) 
3 (6.0%) 
3 (6.0%) 
 
 
2459.66 
(8412.72) 
 
10– 56861 
 
41 (82.0%) 
39 (78.0%) 
 
 
11.48 (4.14)  
 
3–21 
       
34 
 
Cross-
sectional 
(n=67) 
 
49 psychosis 
8 unspecified 
7 transdiagnostic 
3 DD 
 
1 (1.49%) 
61 (91.04%) 
0 
5 (7.46%) 
 
286.49 (507.18) 
 
8 – 2399 
32 (47.76%) 
39 (58.21%) 
13.75 (5.74)  
 
5–24 
 
 
Clinical trial/ 
intervention 
studies 
(n=227) 
 
89 open-label  
     uncontrolled  
47 RCT double-blind  
     placebo- 
     controlled  
58 RCT double-blind  
15 RCT open-label  
11 RCT single-blind  
6 open-label  
   comparison  
1 single-blind,  
   uncontrolled  
 
 
127 psychosis 
20 bipolar 
25 DD 
14 dementia 
6 TS 
6 transdiagnostic 
4 anxiety 
4 BPD 
21 otherb 
 
49 (21.59%) 
142 (62.56%) 
24 (10.57%) 
12 (5.29%) 
 
153.05 (294.61) 
 
6 – 2585 
 
225 (99.12%) 
212 (93.39%) 
 
9.43 (3.54)  
 
2–22 
 
 
 
Note. BPD = borderline personality disorder; DD = developmental disorders; PTSD = posttraumatic stress disorder; TS = Tourette’s syndrome 
 
a Maximum possible score: 25; b 3 conduct disorder; 3 delirium; 3 depression; 2 eating disorders; 2 prodromal psychosis; 2 PTSD; 2 BPD; 1 
cocaine  dependence; 1 drug-induced psychosis; 1 obsessive  compulsive  disorder; 1 somatoform disorders 
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Table 3.  The ten most frequently used measurement scales identified in the review for assessing adverse effects of antipsychotic 
medication. 
 
 
Instrument 
 
Description of content 
 
 
Use across the 
sample 
(n=384) 
 
Assessment domains 
   EPS only  Multi- 
dimensional 
Simpson–Angus 
Extrapyramidal Signs Scale 
(SAS36) 
 
10 items (gait, arm dropping, shoulder/elbow/wrist rigidity, 
head rotation, glabella tap, tremor, salivation, akathisia); 
clinician-rated 5-point Likert scale 
116 (30.21%)
 
X 
 
Abnormal Involuntary 
Movement Scale (AIMS37)   
 
12 items; 4 subscales (orofacial, extremity and truncal 
tardive dyskinesia; condition of teeth /dentures); clinician-
rated 4-point Likert scale 
 
104 (27.08%)
 
X 
 
 
Barnes Akathisia Rating Scale 
(BARS38)  
 
4 items (objective assessment, subjective awareness, 
subjective distress, global clinical assessment); clinician and 
self-rated 5-point Likert scale 
85 (22.14%) 
 
X 
 
The Udvalg for Kliniske 
Undersogelser Side Effect 
Rating Scale (UKU3) 
 
48 items; 3 subscales (autonomic, neurological, other); self-
report 3-point Likert scale 51 (13.28%)a 
  
X 
Extrapyramidal Symptoms 
Rating Scale (ESRS39) 
 
41 items; 4 subscales (Parkinsonism, dystonia, tardive 
dyskinesia, akathisia); self-report 5-point Likert scale 35 (9.11%)
 
X 
 
The Dosage Record Treatment 
Emergent Symptom Scale 
(DOTES40)  
28 items; 8 subscales (neurologic, cardiovascular, psychic, 
hepatic gastrointestinal, hematologic, urologic, other); 
structured interview and 4-point Likert scale 
 
15 (3.91%)
  
X 
36 
 
Liverpool University 
Neuroleptic Side Effect Rating 
Scale (LUNSERS1) 
 
41 items; 7 subscales (extrapyramidal, psychic, 
anticholinergic, autonomic, cutaneous, hormonal, 
miscellaneous); self-report 5-point Likert scale 
14 (3.65%)
  
X 
Arzneimittelsicherheit in der 
Psychiatrie side effect rating 
scale (AMDP41)  
 
47 items; 9 subscales (neurologic, psychic, cardiovascular, 
gastrointestinal, hepatic, cutaneous, urologic, hematologic, 
unspecific); clinician and self-rated 5-point Likert scale 
 
7 (1.82%)
 
 
 
X 
Drug-Induced Extrapyramidal 
Symptoms Scale (DIEPPS42)  
 
9 items (gait, bradykinesia, sialorrhea, rigidity, tremor, 
akathisia, dystonia, dyskinesia, global impact); 5-point 
clinician and self-rated Likert scale 
 
5 (1.30%)
 
X 
 
The St. Hans Rating Scale for 
Extrapyramidal Symptoms 
(SHRS43)  
18 items; 4 subscales (hyperkinesia, Parkinsonism, dystonia, 
akathisia); clinician-rated 6-point Likert scale 6 (1.56%)
 
X 
 
 
Note. Some studies employed more than one instrument. 
a Two studies only used the neurological subscale; one study only used items for sexual dysfunction. 
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Table 4.  Measurement scales identified in the review for assessing the global subjective impact of antipsychotic medication. 
 
 
Instrument 
 
Description 
 
Subscales 
 
 
Abridged sample items 
 
Use across the 
sample (n=384) 
 
 
Drug Attitude 
Inventory  
(DAI5) 
 
 
 
 
30 items; self-report 
dichotomous scale 
 
10-item short version 
 
Positive and negative experiences 
of medication; attitudes to health 
and illness; attitude to physicians, 
control issues, prevention and 
harm. 
 
I feel strange, ‘doped up,’ on medication 
For me, the good things about medication   
     outweigh the bad 
I feel more normal on medication 
 
18 (4.70%) 
 
 
9 (2.34%) 
 
Subjective Well-
Being Under 
Neuroleptics 
scale (SWN)  
 
 
38 items; self-report  
6-point Likert scale13 
 
20-item short version44  
 
 
Emotional regulation, self-control, 
mental functioning, social 
integration and physical functioning 
 
 
I feel very comfortable in my body 
I am full of energy and life 
I am imaginative and full of ideas 
 
 
 
13 (3.40%)  
 
12 (3.13%) 
 
 
Subjects’ 
Response to 
Antipsychotics 
questionnaire 
(SRA14) 
 
 
 
 
74 items; self-report 3-
point Likert scale  
 
Recovery, diminished sociability, 
affective flattening, weight gain, 
sexual anhedonia, sedation, 
increased sleep, EPS 
 
Due to the antipsychotic medication I am  
     more confident 
Due to the antipsychotic medication my  
     creativity has lessened 
Due to the antipsychotic medication I  
     have  less drive to see a great many  
     people 
 
 
3 (0.78%) 
 
Medication 
Adherence Rating 
Scale 
(MARS45) 
 
 
10 items; self-report 
dichotomous scale 
 
Subjective response and medication 
adherence 
 
I feel weird, like a ‘zombie,’ on  
     medication 
It is unnatural for my mind and body to  
     be controlled by medication 
My thoughts are clearer on medication 
 
1 (0.26%) 
38 
 
  
 
Rating of 
Medication 
Influences Scale 
in Schizophrenia 
(ROMI46) 
 
 
 
 
20 items; self-report 3-
point Likert scale  
 
Reasons for medication compliance 
and non-compliance 
 
Are you willing to take your medication  
     because you are pressured or forced   
     to? 
Are you reluctant to take your medication  
     because you feel embarrassed? 
Are you reluctant to take your medication  
     because the side-effects…are too    
     upsetting for you? 
 
 
1 (0.26%) 
 
Reasons for 
Antipsychotic 
Discontinuation/
Continuation 
(RAD-I47) 
 
 
 
 
Open-ended interview 
including a 3-point Likert 
scale 
 
Treatment benefits, adverse events, 
distal reasons other than direct 
medication effects  
 
Patient was unable to form a therapeutic  
     alliance or make a connection with  
     members of the treatment team 
Another person told the patient to stop  
     taking the medication 
The patient experienced intolerable side 
     effects 
 
1 (0.26%) 
 
Satisfaction with 
Antipsychotic 
Medication Scale 
(SWAM48)  
 
 
 
33 items; self-report 5-
point Likert scale  
 
Treatment acceptability and 
medication insight 
 
Antipsychotic medication interfere with  
     my everyday activities 
I find it unpleasant to take antipsychotic  
     medication 
I tolerate the side-effects I get from my  
     antipsychotic medication 
 
 
1 (0.26%) 
Note. Some studies employed more than one instrument. 
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Figure 1. The percentage of studies from each design reporting on different types of antipsychotic adverse effects. 
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Figure 2. The percentage of studies in the sample reporting on antipsychotic adverse effects with either standardised or informal measures. 
 
 
 
 
 
